This article evaluates the effectiveness of neoadjuvant immunotherapy combined with chemotherapy (IC+Chemo) in treating non-small cell lung cancer (NSCLC). This large-scale study involved 1,092 patients from 11 medical centers and compared outcomes between those who received IC+Chemo and those who received chemotherapy alone. Key findings show significantly better outcomes for the IC+Chemo group, with higher rates of pathologic complete response (32.8 percent) and disease-free survival (82 percent) at two years. Patients with squamous cell carcinoma benefited the most from the combined treatment. Additionally, adjuvant therapy following surgery was identified as a critical factor in improving long-term survival, particularly in patients with lower pathologic responses. This study validates the superiority of neoadjuvant immunochemotherapy in improving survival outcomes for NSCLC, helping surgeons and oncologists in refining treatment strategies for better patient care.
You are here:
Treatment Patterns and Clinical Outcomes of Patients With Resectable Non–Small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy: A Large-Scale, Multicenter, Real-World Study (NeoR-World)
Submitted by: Akshay Patel
Source: The Journal of Thoracic and Cardiovascular Surgery
Keywords:
Author(s): Zhenlin Yang, Shuaibo Wang, Haitang Yang, Yina Jiang, Linhai Zhu, Bin Zheng, Honghao Fu, Junliang Ma, Hounai Xie, Zhiqiang Wang, Huayu He, Chuanbao Xia, Renda Li,
Jiachen Xu, Jiefei Han, Xuhua Huang, Yixing Li, Baicheng Zhao, Chenhui Ni, Huajie Xing,
Yangtian Chen, Jingdi Wang, Yuequan Jiang, Yongxiang Song, Yousheng Mao,
Chun Chen, Feng Yao, Guangjian Zhang, Jian Hu, Qi Xue, Shugeng Gao, Jie He
